道琼斯01/13 20:00 Verve Therapeutics 宣布管道进展和预期的2025年里程碑 针对PCSK9的VERVE-102的Heart-2 Phase 10亿临床试验的初步数据预计在2025年第二季度公布,Heart-2试验的剂量已调整至0.6 mg/kg组,VERVE-301被提名。 Verve Therapeutics01/13 13:00 ...
View Verve Therapeutics (VERV) stock price, news, historical charts, analyst ratings, financial information and quotes on Futubull. Trade commission-free with the Futubull stock trading app.
Verve Therapeutics price target increased to $56 from $32 at Stifel Aug. 25, 2022 at 6:49 a.m. ETby Emily Bary Verve Therapeutics stock upgraded to buy from hold at Stifel Aug. 25, 2022 at 6:48 a.m. ETby Emily Bary Autos25 Stocks That Could Rise on a Short Squeeze ...
A high-level overview of Verve Therapeutics, Inc. (VERV) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Verve Therapeutics Inc. analyst estimates, including VERV earnings per share estimates and analyst recommendations.
智通财经获悉,Verve Therapeutics(VERV.US)的股价在盘前交易中暴跌,此前该公司表示,出于安全考虑,暂停了一项针对高胆固醇患者的基因编辑治疗研究的注册,这给前景光明的新医学领域带来了挫折。截至发稿,该公司股价周二盘前一度下跌38%,随后收窄至34.43%。
Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Verve Therapeutics (VERV – Research Report). The associated pri...
Price –USD Fair Value – Upside 4.30 - 19.34 52-week range Create Chart Create Model Add To Watchlist Analysis Fiscal Years The following section summarizes insights on Verve Therapeutics Inc's Net Income to Stockholders: Dec 2015Dec 2017Dec 2019Dec 2021Dec 2023-200 M-150 M-100 M-50 M0 ...
Investors responded to the clinical hold announcement with a stock selloff that sent Verve’s shares tumbling 27% in trading as of midday Monday, to $22.85 from Friday’s closing price of $31.29. Impact seen on Beam Therapeutics Mani Foroohar, MD, senior managing director, genetic medicines ...
Verve Therapeutics Inc. options data by MarketWatch. View VERV option chain data and pricing information for given maturity periods.